Navigation Links
Enzyme allows B cells to resist death, leading to leukemia

B cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in adults and is characterized by the progressive accumulation of mature B lymphocytes in the blood, bone marrow, and lymphatic tissues. It is believed that in the early stages of disease, B-CLL is the result of an undefined defect in the programmed signals that trigger normal B cell death (apoptosis). Livio Trentin and colleagues from Padua University School of Medicine now demonstrate that high levels of expression and altered cellular location of an enzyme in B cells known as Lyn, contributes to the development of B-CLL.

The authors examined leukemia cells from 40 patients with B-CLL and compared them with lymphocytes from normal donors. They found that Lyn was markedly overexpressed in CLL cells and an unusual amount of the enzyme was found in the cell cytosol. In addition, the enzyme was constantly active compared with levels of activity in normal donor cells. The authors went on to show that inhibition of Lyn was able to restore the process of cell apoptosis to normal and treatment of malignant cells with drugs that induce cell death decreased both Lyn expression levels and activity ?suggesting a direct correlation between high Lyn activity and the ability of these B cells to resist apoptosis. The authors suggest that Lyn is involved in the development of B-CLL and that this enzyme therefore represents an attractive target for therapy. The study will appear online on January 13 in advance of publication in the February 1 print edition of the Journal of Clinical Investigation.
'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
2. Novel Enzyme Shows Potential As An Anti-HIV Target
3. Enzyme shown to help protect genomic stability
4. Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol
5. Enzymes newly discovered role may make it target for arthritis treatment
6. Promiscuous Catalytic Activity Possessed by Novel Enzyme Structure
7. Gene Bridges And Covalys To Develop Restriction-Enzyme-Free SNAP-tag Gene Fusion Kits
8. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
9. Enzyme affects hypertension by controlling salt levels in body
10. Enzyme inhibitors block replication of SARS virus
11. Enzyme crystal structure reveals unexpected genome repair functions
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/30/2019)... ... October 30, 2019 , ... The 2019 Precision Agriculture ... which participants will learn about precision agriculture tools used to enhance beef and ... , Participants will have the opportunity to visit Virginia Tech’s agricultural research center, ...
(Date:10/29/2019)... (PRWEB) , ... October 29, ... ... of enterprise software solutions for biopharmaceutical R&D, today announced that Octapharma, one ... Bioprocess® platform to support the development and manufacturing of therapeutic proteins ...
(Date:10/26/2019)... ... 24, 2019 , ... World Cord Blood Day (WCBD) takes place on November ... learn about the current and future uses of cord blood stem cells, and the ... to treat and cure over 80 different life-threatening diseases, including leukemia, lymphoma, and sickle ...
Breaking Biology News(10 mins):
(Date:11/2/2019)... ... October 31, 2019 , ... ... Biotechnologies in a live webinar on Friday, November 15, 2019 ... , Immunosequencing, the science of profiling T-cell receptors (TCRs) and B-cell receptors ...
(Date:10/29/2019)... ... October 29, 2019 , ... Modality ... Silver sponsorship and cold chain validation workshop at the Biomanufacturing World Summit (BMWS19) ... Diego, California. , The Biomanufacturing World Summit brings together pharmaceutical executives, ...
(Date:10/22/2019)... ... October 22, 2019 , ... Enplug , ... Mass Notification System into its digital signage platform. The collaboration brings one of ... possible for users to leverage their existing digital signage networks to quickly disseminate ...
(Date:10/10/2019)... (PRWEB) , ... October 09, 2019 , ... ... Amy Abernethy, MD, PhD, Principal Deputy Commissioner, FDA, as a newly-confirmed keynote speaker ... October 2019 in Las Vegas, Nevada USA. , Dr. Abernethy, a hematologist/oncologist and ...
Breaking Biology Technology: